For years, the clinical conversation around retatrutide — commonly referred to as reta in patient communities — has centered on its remarkable weight loss results in people without type 2 diabetes. The Phase 2 obesity trial published in the New England Journal of Medicine in 2023 excluded participants with type 2 diabetes entirely, meaning a large and medically complex population had been left waiting for their own data. That data has now arrived.
TRANSCEND-T2D-1 is a double-blind, randomised, Phase 3 trial studying retatrutide specifically in people with type 2 diabetes and inadequate glycaemic control despite diet and exercise. The trial results were published on PubMed on June 6, 2026, and represent a pivotal expansion of the clinical evidence base for this triple agonist compound. The source citation is available at https://pubmed.ncbi.nlm.nih.gov/42250575/.
Retatrutide (LY3437943), developed by Eli Lilly and Company, works simultaneously on three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This mechanism — sometimes called the "triple G" in online patient communities — distinguishes it from earlier generation agents that target only one or two of these pathways. The glucagon receptor component, in particular, is thought to drive additional energy expenditure and metabolic benefit beyond what dual GLP-1/GIP agonists like tirzepatide can provide.
TRANSCEND-T2D-1 enrolled participants with type 2 diabetes who were not achieving adequate glycaemic control through lifestyle measures alone, making it a clinically relevant and high-need population. The trial design is double-blind and randomised, consistent with the rigorous standards expected of a Phase 3 registration-quality study.
The TRANSCEND-T2D-1 trial provides the first Phase 3 glycaemic efficacy data for retatrutide in people living with type 2 diabetes. The primary endpoints focused on HbA1c reduction and the proportion of participants achieving glycaemic targets — two measures that define meaningful diabetes management in clinical practice.
This trial is significant because the Phase 2 obesity program deliberately excluded anyone with an HbA1c of 6.5% or above, fasting glucose of 126 mg/dL or above, or a random glucose of 200 mg/dL or above. TRANSCEND-T2D-1 was specifically designed to fill that gap, studying a population where both glucose lowering and weight reduction carry direct cardiovascular and metabolic consequences.
Given the mechanism of action — GIP, GLP-1, and glucagon receptor co-agonism — retatrutide is positioned to address multiple drivers of hyperglycaemia simultaneously. GLP-1 receptor activation enhances glucose-stimulated insulin secretion and suppresses glucagon. GIP receptor activation provides additional insulinotropic and potentially cardioprotective effects. The glucagon receptor component, while counterintuitive at first glance, is titrated to promote fat oxidation and thermogenesis rather than raise blood glucose, particularly in the context of concurrent GLP-1 activity.
For context, the weight loss data from TRIUMPH-4 — the Phase 3 obesity trial — demonstrated a mean body weight reduction of 28.7% at the 12mg dose over 68 weeks, the highest ever recorded in a Phase 3 obesity trial. For people with type 2 diabetes, where even 10–15% weight loss can produce durable glycaemic remission in some patients, the magnitude of weight reduction seen with reta in non-diabetic populations suggests meaningful downstream glycaemic benefit may be achievable in the T2D population as well.
To place TRANSCEND-T2D-1 in context, it helps to compare retatrutide's profile to established agents across both weight loss and glycaemic dimensions. The table below uses Phase 3 trial data from published or publicly disclosed sources.
| Agent | Mechanism | Trial | Duration | Population | Mean Weight Loss |
|---|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 agonist | STEP-1 | 68 weeks | Obesity, no T2D | ~14.9% |
| Tirzepatide 15mg | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | Obesity, no T2D | ~20.9% |
| Retatrutide 12mg | GLP-1 / GIP / glucagon triple agonist | TRIUMPH-4 | 68 weeks | Obesity, no T2D | 28.7% |
| Retatrutide | GLP-1 / GIP / glucagon triple agonist | TRANSCEND-T2D-1 | Phase 3 (ongoing) | Type 2 diabetes | Phase 3 data published June 2026 |
It is worth noting that weight loss efficacy typically attenuates in populations with type 2 diabetes compared to those without — a pattern seen consistently with both semaglutide and tirzepatide across their respective trial programs. Whether retatrutide's glucagon receptor component partially offsets this attenuation in the T2D setting is one of the most clinically meaningful questions TRANSCEND-T2D-1 is positioned to answer.
The safety profile of retatrutide has been reasonably well characterised through Phase 2 data, and TRANSCEND-T2D-1 provides the first opportunity to evaluate that profile in a population with type 2 diabetes — a group that may carry additional baseline cardiovascular, renal, and neuropathic risk.
From the Phase 2 obesity trial, the most frequently reported adverse events were gastrointestinal in nature: nausea, diarrhea, and vomiting. These were dose-dependent and most prominent during the titration period, consistent with the class effect seen with all GLP-1-containing agents. At the 12mg dose in Phase 2, hyperesthesia and dysesthesia were reported in 12.9% of participants versus 1.4% on placebo — a signal that gained further attention in TRIUMPH-4, where dysesthesia was reported in 20.9% of participants at the 12mg dose.
In TRIUMPH-4, overall discontinuation rates were 18.2% at 12mg versus 4.0% for placebo, with some discontinuations attributed to perceived excessive weight loss — an unusual but important clinical consideration at this magnitude of efficacy. In a population with type 2 diabetes, medication management (particularly insulin and sulfonylureas) would require proactive adjustment as glycaemic control improves and weight declines.
Hypoglycaemia risk in the context of concomitant diabetes medications is a key safety consideration that TRANSCEND-T2D-1 is designed to address. The glucagon receptor agonism in retatrutide theoretically provides some counter-regulatory activity, but the net effect on hypoglycaemia frequency — particularly in patients on insulin — requires careful Phase 3 characterisation.
As of April 2026, Eli Lilly had not yet filed a New Drug Application (NDA) with the FDA for retatrutide, and an FDA approval timeline has not been publicly confirmed. TRANSCEND-T2D-1 represents a meaningful step toward building the comprehensive Phase 3 dataset that a regulatory submission would require — not only for an obesity indication, but potentially for a distinct type 2 diabetes indication as well.
The publication of TRANSCEND-T2D-1 data on June 6, 2026, signals that the Phase 3 program is generating results at pace. For a drug that already produced the highest mean weight loss ever recorded in a Phase 3 obesity trial — 28.7% at 12mg in TRIUMPH-4 over 68 weeks — the addition of robust T2D efficacy and safety data substantially strengthens the overall regulatory and clinical case.
Regulators will be looking for evidence of durable HbA1c reduction, cardiovascular safety, and a manageable adverse event profile in a population that already carries elevated cardiometabolic risk. TRANSCEND-T2D-1's double-blind, randomised design is well suited to generate that evidence. The broader TRIUMPH program, combined with the TRANSCEND diabetes data, positions retatrutide as potentially the most comprehensively studied triple agonist to date.
For clinicians managing patients with both obesity and type 2 diabetes — two conditions that are deeply intertwined — the prospect of a single weekly injection addressing insulin resistance, food noise reduction, and substantial fat mass reduction simultaneously represents a meaningful shift in what pharmacotherapy can accomplish.
If you are following the development of retatrutide and want to stay informed as Phase 3 data matures and the regulatory pathway becomes clearer, consider joining the waitlist at glp3md.com. The waitlist is a way to stay updated and express your interest — it does not guarantee access to medication, a prescription, or any form of treatment. Retatrutide is not FDA-approved, and no promises are made about future availability. What glp3md does offer is a commitment to sharing accurate, peer-reviewed clinical information as it emerges — so that when this therapy does reach patients, those patients are prepared.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.